• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全长 TSH 受体与抗体 K1-70™复合物的结构。

Structure of full-length TSH receptor in complex with antibody K1-70™.

机构信息

FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK.

出版信息

J Mol Endocrinol. 2022 Dec 7;70(1). doi: 10.1530/JME-22-0120. Print 2023 Jan 1.

DOI:10.1530/JME-22-0120
PMID:36069797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9782461/
Abstract

Determination of the full-length thyroid-stimulating hormone receptor (TSHR) structure by cryo-electron microscopy (cryo-EM) is described. The TSHR complexed with human monoclonal TSHR autoantibody K1-70™ (a powerful inhibitor of TSH action) was detergent solubilised, purified to homogeneity and analysed by cryo-EM. The structure (global resolution 3.3 Å) is a monomer with all three domains visible: leucine-rich domain (LRD), hinge region (HR) and transmembrane domain (TMD). The TSHR extracellular domain (ECD, composed of the LRD and HR) is positioned on top of the TMD extracellular surface. Extensive interactions between the TMD and ECD are observed in the structure, and their analysis provides an explanation of the effects of various TSHR mutations on TSHR constitutive activity and on ligand-induced activation. K1-70™ is seen to be well clear of the lipid bilayer. However, superimposition of M22™ (a human monoclonal TSHR autoantibody which is a powerful stimulator of the TSHR) on the cryo-EM structure shows that it would clash with the bilayer unless the TSHR HR rotates upwards as part of the M22™ binding process. This rotation could have an important role in TSHR stimulation by M22™ and as such provides an explanation as to why K1-70™ blocks the binding of TSH and M22™ without activating the receptor itself.

摘要

通过冷冻电镜(cryo-EM)确定全长促甲状腺激素受体(TSHR)结构。描述了与人类单克隆 TSHR 自身抗体 K1-70™(一种强大的 TSH 作用抑制剂)结合的 TSHR 复合物被去污剂溶解、纯化为均相并通过 cryo-EM 分析。该结构(全局分辨率为 3.3Å)是一个单体,所有三个结构域均可见:富含亮氨酸结构域(LRD)、铰链区(HR)和跨膜结构域(TMD)。TSHR 细胞外结构域(ECD,由 LRD 和 HR 组成)位于 TMD 细胞外表面的顶部。结构中观察到 TMD 和 ECD 之间存在广泛的相互作用,对其进行分析解释了各种 TSHR 突变对 TSHR 组成型活性和配体诱导激活的影响。K1-70™ 被认为远离脂质双层。然而,将 M22™(一种人类单克隆 TSHR 自身抗体,是 TSHR 的强大刺激剂)叠加在 cryo-EM 结构上表明,除非 TSHR HR 向上旋转作为 M22™结合过程的一部分,否则它会与双层发生冲突。这种旋转可能在 M22™刺激 TSHR 中起重要作用,因此解释了为什么 K1-70™ 阻止 TSH 和 M22™ 的结合而不激活受体本身。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/2e9a9c7c6173/JME-22-0120fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/1d89d38881a0/JME-22-0120fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/7c02c0659219/JME-22-0120fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/c336338468da/JME-22-0120fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/2e9a9c7c6173/JME-22-0120fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/1d89d38881a0/JME-22-0120fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/7c02c0659219/JME-22-0120fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/c336338468da/JME-22-0120fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f7a/9782461/2e9a9c7c6173/JME-22-0120fig4.jpg

相似文献

1
Structure of full-length TSH receptor in complex with antibody K1-70™.全长 TSH 受体与抗体 K1-70™复合物的结构。
J Mol Endocrinol. 2022 Dec 7;70(1). doi: 10.1530/JME-22-0120. Print 2023 Jan 1.
2
Crystal structure of a ligand-free stable TSH receptor leucine-rich repeat domain.无配体稳定的 TSH 受体富含亮氨酸重复结构域的晶体结构。
J Mol Endocrinol. 2019 Apr 1;62(3):117-128. doi: 10.1530/JME-18-0213.
3
Similarities and differences in interactions of thyroid stimulating and blocking autoantibodies with the TSH receptor.甲状腺刺激和阻断自身抗体与 TSH 受体相互作用的异同。
J Mol Endocrinol. 2012 Aug 30;49(2):137-51. doi: 10.1530/JME-12-0040. Print 2012 Oct.
4
Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure.基于突变和对受体晶体结构此区域模糊性的重新评估,深入了解甲状腺刺激自身抗体与促甲状腺素受体 N 端的相互作用。
Thyroid. 2011 Sep;21(9):1013-20. doi: 10.1089/thy.2011.0147. Epub 2011 Aug 11.
5
The full-length TSH receptor is stabilized by TSH ligand.全长 TSH 受体受 TSH 配体稳定。
J Mol Graph Model. 2024 Jun;129:108725. doi: 10.1016/j.jmgm.2024.108725. Epub 2024 Feb 11.
6
Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70 a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity.K1-70是一种对促甲状腺激素(TSH)受体具有TSH拮抗活性的人源单克隆自身抗体,对其进行的毒理学、药代动力学及安全性的临床前研究。
Auto Immun Highlights. 2019 Nov 7;10(1):11. doi: 10.1186/s13317-019-0121-9. eCollection 2019 Dec.
7
Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody.TSHR 与阻断型 TSHR 自身抗体结合的晶体结构。
J Mol Endocrinol. 2011 Feb 15;46(2):81-99. doi: 10.1530/JME-10-0127. Print 2011 Apr.
8
TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.具有激动剂、拮抗剂和反向激动剂活性的促甲状腺激素受体单克隆抗体。
Methods Enzymol. 2010;485:393-420. doi: 10.1016/B978-0-12-381296-4.00022-1.
9
Hormone- and antibody-mediated activation of the thyrotropin receptor.促甲状腺激素受体的激素和抗体介导的激活。
Nature. 2022 Sep;609(7928):854-859. doi: 10.1038/s41586-022-05173-3. Epub 2022 Aug 8.
10
Structure and activation of the TSH receptor transmembrane domain.促甲状腺激素受体跨膜结构域的结构与激活
Auto Immun Highlights. 2017 Dec;8(1):2. doi: 10.1007/s13317-016-0090-1. Epub 2016 Dec 5.

引用本文的文献

1
Expression, immunogenicity and clinical significance analysis of thyroid‑stimulating hormone receptor fusion proteins.促甲状腺激素受体融合蛋白的表达、免疫原性及临床意义分析
Mol Med Rep. 2025 Oct;32(4). doi: 10.3892/mmr.2025.13639. Epub 2025 Aug 1.
2
Expression of the Extracellular Domain of the Thyrotropin Receptor Based on mRNA Isolated from Thyroid Tissue and Whole Blood of Patients with Toxic Diffuse Goiter (Graves' Disease).基于从毒性弥漫性甲状腺肿(格雷夫斯病)患者的甲状腺组织和全血中分离的mRNA的促甲状腺激素受体细胞外结构域的表达。
Bull Exp Biol Med. 2025 Feb;178(4):431-436. doi: 10.1007/s10517-025-06351-9. Epub 2025 Mar 28.
3

本文引用的文献

1
TSH receptor specific monoclonal autoantibody K1-70 targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial.促甲状腺激素受体特异性单克隆自身抗体 K1-70 靶向 Graves 病和 Graves 眼病患者的促甲状腺激素受体-一项 I 期临床试验结果。
Clin Endocrinol (Oxf). 2022 Jun;96(6):878-887. doi: 10.1111/cen.14681. Epub 2022 Feb 6.
2
Structures of full-length glycoprotein hormone receptor signalling complexes.全长糖蛋白激素受体信号复合物的结构。
Nature. 2021 Oct;598(7882):688-692. doi: 10.1038/s41586-021-03924-2. Epub 2021 Sep 22.
3
Highly accurate protein structure prediction for the human proteome.
A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.
甲状腺眼病发病机制的全面综述:从免疫失调到新的诊断和治疗方法。
Int J Mol Sci. 2024 Oct 29;25(21):11628. doi: 10.3390/ijms252111628.
4
The changing landscape of thyroid eye disease: current clinical advances and future outlook.甲状腺眼病的变化格局:当前临床进展及未来展望。
Eye (Lond). 2024 Jun;38(8):1425-1437. doi: 10.1038/s41433-024-02967-9. Epub 2024 Feb 19.
5
Mechanisms of thyrotropin receptor-mediated phenotype variability deciphered by gene mutations and M453T-knockin model.通过基因突变和 M453T 敲入模型解析促甲状腺激素受体介导的表型变异性的机制。
JCI Insight. 2024 Jan 9;9(4):e167092. doi: 10.1172/jci.insight.167092.
6
Receptor modulators associated with the hypothalamus -pituitary-thyroid axis.与下丘脑 - 垂体 - 甲状腺轴相关的受体调节剂。
Front Pharmacol. 2023 Dec 4;14:1291856. doi: 10.3389/fphar.2023.1291856. eCollection 2023.
7
Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.别构调节 G 蛋白偶联受体:从分子机制多样性到多个别构结合位点及其配体。
Int J Mol Sci. 2023 Mar 24;24(7):6187. doi: 10.3390/ijms24076187.
高精准度的人类蛋白质组蛋白结构预测。
Nature. 2021 Aug;596(7873):590-596. doi: 10.1038/s41586-021-03828-1. Epub 2021 Jul 22.
4
Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.用 K1-70 阻断促甲状腺激素受体治疗滤泡性甲状腺癌、Graves 病和 Graves 眼病患者。
Thyroid. 2021 Oct;31(10):1597-1602. doi: 10.1089/thy.2021.0053. Epub 2021 Jul 8.
5
Modulating TSH Receptor Signaling for Therapeutic Benefit.调节促甲状腺激素受体信号以获得治疗益处。
Eur Thyroid J. 2020 Dec;9(Suppl 1):66-77. doi: 10.1159/000511871. Epub 2020 Nov 23.
6
TSH Receptor Homodimerization in Regulation of cAMP Production in Human Thyrocytes .促甲状腺激素受体同源二聚体在人甲状腺细胞中环腺苷酸产生调节中的作用。
Front Endocrinol (Lausanne). 2020 Apr 30;11:276. doi: 10.3389/fendo.2020.00276. eCollection 2020.
7
Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70 a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity.K1-70是一种对促甲状腺激素(TSH)受体具有TSH拮抗活性的人源单克隆自身抗体,对其进行的毒理学、药代动力学及安全性的临床前研究。
Auto Immun Highlights. 2019 Nov 7;10(1):11. doi: 10.1186/s13317-019-0121-9. eCollection 2019 Dec.
8
Real-time cryo-electron microscopy data preprocessing with Warp.使用 Warp 进行实时低温电子显微镜数据预处理。
Nat Methods. 2019 Nov;16(11):1146-1152. doi: 10.1038/s41592-019-0580-y. Epub 2019 Oct 7.
9
Crystal structure of a ligand-free stable TSH receptor leucine-rich repeat domain.无配体稳定的 TSH 受体富含亮氨酸重复结构域的晶体结构。
J Mol Endocrinol. 2019 Apr 1;62(3):117-128. doi: 10.1530/JME-18-0213.
10
Structure of the glucagon receptor in complex with a glucagon analogue.胰高血糖素受体与胰高血糖素类似物复合物的结构。
Nature. 2018 Jan 3;553(7686):106-110. doi: 10.1038/nature25153.